Cetuximab metastatic colorectal cancer strategy (ERMES) study: A phase III randomized two arm study with FOLFIRI + cetuximab until disease progression compared to FOLFIRI + cetuximab for 8 cycles followed by cetuximab alone until disease progression in first-line treatment of patients with RAS and BRAF wild type metastatic colorectal cancer.
Carmine Pinto(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Armando Orlandi(Agostino Gemelli University Polyclinic), Carlo Barone(Università Cattolica del Sacro Cuore), Salvatore Pisconti(Ospedale SS. Annunziata), Emiliano Tamburini(Ospedale Infermi di Rimini), Stefania Gori(Ospedale Sacro Cuore Don Calabria), Francesco Di Costanzo, Alberto Zaniboni(Fondazione Poliambulanza Istituto Ospedaliero), Lazzaro Repetto, Evaristo Maiello(Casa Sollievo della Sofferenza), Héctor Soto Parrà, Francesco Ferraù(Université Paris-Sud), Domenico Corsi(Ospedale San Carlo), Giuseppe Tonini(Campus Bio Medico University Hospital), Bruno Daniele(Azienda Ospedaliera G.Rummo), Maria Giulia Zampino(Azienda Ospedaliera Universitaria Pisana), Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), Rosario V. Iaffaioli(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Nicola Normanno(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Giovanni Luca Frassinetti(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori)
Cited by 3
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.1k